^
    1d
    Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation
    |
    Lynparza (olaparib) • cisplatin • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    1d
    Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (clinicaltrials.gov)
    P3, N=953, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 negative
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed
    2d
    NEOREM-NEO-1: Neo-adjuvant Immunotherapy in Patients With Localized Melanoma (clinicaltrials.gov)
    P2, N=50, Recruiting, UNICANCER | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, Jiangsu Cancer Institute & Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    2d
    TORCH-OPTIMA: Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer (clinicaltrials.gov)
    P2, N=114, Not yet recruiting, Fudan University
    New P2 trial • Mismatch repair • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    AK104-310: A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P3, N=760, Recruiting, Akeso | Not yet recruiting --> Recruiting
    Enrollment open
    |
    oxaliplatin • Kaitanni (cadonilimab) • Teysuno (gimeracil/oteracil/tegafur)
    2d
    Cytomegalovirus gastritis following immune checkpoint inhibitor-associated gastritis induced by ipilimumab and nivolumab therapy in a patient with renal cell carcinoma. (PubMed, Clin J Gastroenterol)
    Valganciclovir was initiated, and prednisolone was discontinued. Although irAE gastritis is a rare complication of ICI therapy, it should be considered in patients presenting with upper gastrointestinal symptoms during treatment. The management of irAE gastritis requires vigilance for opportunistic infections, timely histopathological evaluation, and careful differentiation from viral infections, especially in cases refractory to corticosteroids.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Valcyte (valganciclovir)
    3d
    First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    docetaxel • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    3d
    A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (clinicaltrials.gov)
    P3, N=378, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P3 trial
    |
    cisplatin • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    3d
    Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. (PubMed, Nat Commun)
    In this phase I study, we test a pooled synthetic long peptide vaccine targeting the six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D) with ipilimumab and nivolumab in resected pancreatic adenocarcinoma. The vaccine also generates cross-reactive T cells that recognize more than one mutant KRAS antigen. These findings support the safety and diverse anti-tumor immunity of mutant KRAS vaccines (NCT04117087).
    P1 data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12 • KRAS G13
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    Outcomes of patients with melanoma brain metastases treated with ipilimumab and nivolumab with or without upfront comprehensive stereotactic radiosurgery. (PubMed, Neurooncol Adv)
    In this retrospective study, upfront cSRS was more often used in patients with higher-risk MBM and was associated with improved intracranial control, although no significant survival benefit was observed. These findings suggest that starting ipi/nivo alone may be reasonable for lower-risk MBM, but prospective studies are needed to guide optimal integration of cSRS.
    Journal • PD(L)-1 Biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    AK104-IIT-C-N1-0004: A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting | Trial completion date: Nov 2025 --> Nov 2026
    Enrollment closed • Trial completion date
    |
    Stivarga (regorafenib) • Kaitanni (cadonilimab)